上海醫藥(02607.HK):前三季度淨利潤48.14億元 同比上升7.35%
格隆匯10月27日丨上海醫藥(02607.HK)發佈公吿,2022年1-9月,公司主營業務繼續保持較快增長,實現營業收入1,746.12億元(幣種為人民幣,下同),同比增長8.47%。其中:醫藥工業實現銷售收入197.93億元,同比增長5.35%;醫藥商業實現銷售收入1,548.19億元,同比增長8.89%。2022年7-9月,公司實現營業收入629.04億元,同比增長12.86%。其中:醫藥工業銷售收入67.43億元,同比增長9.02%;醫藥商業銷售收入561.61億元,同比增長13.34%。
2022年1-9月,公司實現歸屬於上市公司股東的淨利潤48.14億元,同比上升7.35%。醫藥工業和商業主營業務利潤繼續保持良好增長態勢,其中:工業板塊貢獻利潤16.52億元,同比增長4.01%;商業板塊貢獻利潤24.13億元,同比增長15.94%;主要參股企業貢獻利潤4.78億元,同比下降32.40%。歸屬於上市公司股東的扣除非經常性損益的淨利潤為36.98億元,同比增長4.31%。扣除參股企業投資收益,前三季度扣除非經常性損益後的歸母淨利潤同比增長14.11%。2022年7-9月實現歸屬於上市公司股東的淨利潤11.18億元,同比上升22.02%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.